Retrospective Cohort Study
Copyright ©The Author(s) 2017.
World J Hepatol. Dec 28, 2017; 9(36): 1322-1331
Published online Dec 28, 2017. doi: 10.4254/wjh.v9.i36.1322
Figure 1
Figure 1 Cumulative survival of the overall cirrhotic patients with Barcelona Clinic Liver Cancer C stage hepatocellular carcinoma included in the study. The solid line shows the overall survival and the dotted lines the 95%CIs.
Figure 2
Figure 2 Plot of the scaled Schoenfeld residuals over time for alphafetoprotein serum level > 200 ng/mL (A) and disease control (B). The solid line shows the log of hazard ratio (beta) as a function of survival time with the 95%CI (dotted lines). The average beta value obtained at the Cox model without any time-adjustment is also reported (solid red line).

  • Citation: Ponziani FR, Spinelli I, Rinninella E, Cerrito L, Saviano A, Avolio AW, Basso M, Miele L, Riccardi L, Zocco MA, Annicchiarico BE, Garcovich M, Biolato M, Marrone G, De Gaetano AM, Iezzi R, Giuliante F, Vecchio FM, Agnes S, Addolorato G, Siciliano M, Rapaccini GL, Grieco A, Gasbarrini A, Pompili M. Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. World J Hepatol 2017; 9(36): 1322-1331
  • URL: https://www.wjgnet.com/1948-5182/full/v9/i36/1322.htm
  • DOI: https://dx.doi.org/10.4254/wjh.v9.i36.1322